Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
328 studies found for:    KRAS
Show Display Options
Rank Status Study
1 Unknown  KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009
Condition: Colorectal Carcinoma
2 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
3 Recruiting Study of K-ras Status Switch in K-ras Native Patients With Metastatic Colorectal Tumors Treated With FOLFIRI-Cetuximab as First-line Treatment
Condition: Colorectal Cancer Metastatic
Intervention: Drug: FOLFIRI + Cetuximab
4 Completed MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Mek Inhibitor MSC1936369B;   Drug: Placebo;   Drug: FOLFIRI
5 Recruiting Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Condition: Cancer
Intervention: Genetic: KRAS-variant
6 Active, not recruiting
Has Results
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244;   Drug: Erlotinib;   Drug: AZD6244 + Erlotinib
7 Not yet recruiting Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Conditions: Colorectal Cancer Metastatic;   Liver Metastases;   KRAS Mutated Colorectal Cancer
Interventions: Drug: Modified FOLFOX6;   Biological: Aflibercept;   Procedure: Surgery
8 Recruiting A Trial to Assess Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Condition: Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Interventions: Drug: Sorafenib and irinotecan combination;   Drug: Sorafenib monotherapy;   Drug: Irinotecan monotherapy
9 Completed Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
10 Enrolling by invitation Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe
Condition: Metastatic Colorectal Cancer
Intervention: Other: Other
11 Completed KRAS Wild-type Metastatic Colorectal Cancer Trial
Condition: Colorectal Cancer
Interventions: Drug: Dacogen™ (decitabine);   Drug: Vectibix® (panitumumab)
12 Active, not recruiting Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab, erlotinib;   Drug: bevacizumab;   Drug: low dose capecitabine
13 Active, not recruiting Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients
Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244;   Drug: docetaxel;   Drug: Placebo
14 Withdrawn Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: capecitabine and cetuximab
15 Completed Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
Condition: Colorectal Neoplasms
16 Completed Ph2 Biomarker (Mechanism of K-ras Dependency) in Wt KRAS Metastatic Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Panitumumab;   Drug: AMG 479;   Drug: Irinotecan
17 Active, not recruiting A Phase 2 Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
Condition: Colorectal Cancer (CRC)
Intervention: Drug: Cetuximab
18 Active, not recruiting Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Other: Best Supportive Care;   Drug: Panitumumab
19 Unknown  Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Conditions: Colorectal Cancer;   KRAS Wildtype;   After Resection of Liver Metastases
Interventions: Drug: Folic Acid;   Drug: 5-FU;   Drug: Oxaliplatin;   Drug: Panitumumab
20 Completed K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications
Condition: Non-Small Cell Lung Cancer

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years